Visceral Fat and Cardiometabolic Risk
Optimal Visceral Fat Area Cutoffs for Screening Cardiometabolic Risk: a Large-scale Population-based Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Healthy children and adolescents aged 6-18 years
Exclusion Criteria:
Heart disease Kidney disease Thyroid disease Individuals who take hormone medication Missing data for anthropometry
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cardiometabolic risk group
|
No intervention was involved in this study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visceral fat area cutoffs and cardiometabolic risk
Time Frame: 2 years
|
Based on dual-energy X-ray measurements of visceral fat area, age- and sex-specific visceral fat area cutoffs for screening cardiometabolic risk was developed and validated.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2012062
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cohort Study
-
NCT07321795Not yet recruitingCohort Study | OVCF Database
-
NCT03735251CompletedLeft Ventricular Diastoic Dysfunction Cohort Study
-
NCT07207863RecruitingCohort Study | Natural Population | Northwest Region of China
-
NCT06931925Not yet recruiting
-
NCT06121804RecruitingCohort Study | Organ Transplantation | Immunosuppressive Agents
-
NCT00679640CompletedObservational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France (SISTOLA)Heart Failure | Cohort Study
-
NCT05855720RecruitingMental Health | Cohort Studies | Psychiatry | Evaluation Study | Cross-sectoral Treatment | Flexible and Integrated Treatment | FIT
-
NCT07249996RecruitingCohort Study | Viral Infections | Lower Respiratory Tract Infection (LRTI) | Respiratory Tract Infections (RTI)
-
NCT04727359CompletedCohort Study | Evaluation | Mental Health Care | Cross-sectoral Treatment | Flexible and Integrated Treatment | FIT64b | Child and Adolescent Psychiatry
Clinical Trials on No intervention
-
NCT06980844Not yet recruitingInterstitial Lung Disease
-
NCT02746445Completed
-
NCT05345054CompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social Behavior
-
NCT01923415CompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, Discoid
-
NCT06134739RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | Ablation
-
NCT03305484CompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein Staining
-
NCT06686342RecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in Vitro
-
NCT03385811UnknownIntention to Stay, Turnover Behavior